During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Ponatinib improved MRD negativity and safety in Ph+ ALL patients in the PHALLcon study, supporting its role as a potent TKI ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A new risk model uses objective clinical data to predict cure or relapse in Hodgkin lymphoma, with future plans to guide treatment and survivorship care.

Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation ...

A panelist notes that while new treatments like luspatercept and imetelstat offer hope beyond traditional erythropoiesis-stimulating agents—which fail in many patients and provide limited response ...

A panelist highlights that after initial hemoglobin decline despite dose escalation, further increasing luspatercept dosing led to transfusion independence and hemoglobin improvement, underscoring the ...

An expert discusses how radiopharmaceuticals such as radium-223 offer a valuable different mechanism of action in treating advanced prostate cancer, requiring careful patient selection, safety ...

A panelist emphasizes that recent real-world retrospective data from 103 first-line luspatercept-treated patients closely align with, and even slightly exceed, COMMANDS trial results—demonstrating ...